Welsh Government has approved new advice from the All Wales Medicines Strategy Group (AWMSG) for two medicines.
- dolutegravir/lamivudine (Dovato®) was recommended to treat human immunodeficiency virus (HIV) infection in adults and adolescents over 12 years old who weigh at least 40 kg.
- plerixafor (Mozobil®) was recommended to help collect stem cells from children over one year old with solid tumors or lymphoma, for later transplantation. Plerixafor helps to release stem cells into the blood stream and is given in combination with granulocyte-colony stimulating factor (GCSF) when stem cells have not mobilised enough with G-GSF treatment alone. Plerixafor is already used to help collect stem cells in adults with lymphoma or multiple myeloma.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.